The Latest Breaking News from Sanofi

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

We may think of air pollution as an outdoor problem, made up of car exhaust and smog. But if the air inside our homes is polluted, this can also affect our health.

Shenzhen Component Index closed down 0.31%

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell in December 2024?

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

Blue-chip stocks offer stability and consistent growth irrespective of market conditions. Thus, blue chip names Lockheed Martin (LMT), Regeneron Pharmaceuticals (REGN), and Cigna Group (CI) could be prudent additions to your portfolios. These stocks are Strong Buy-rated in our proprietary POWR Ratings system. Read on.

AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma giant Sanofi.

The Paris Olympics have been a showcase not only for athletic prowess but also for therapies such as ice baths and osteopathy which have little scientifically proven medical value, according to experts.

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….